Iron Deficiency and Anemia in Women: When to Screen

Abstract

Iron deficiency and iron deficiency anemia (IDA) are prevalent and consequential health concerns among women worldwide, particularly impacting reproductive-aged, pregnant, and peri-menopausal populations. This review synthesizes recent epidemiological data, elucidates the underlying mechanisms, explores risk factors, clinical presentations, and diagnostic approaches, and summarizes current management strategies with an emphasis on evidence-based and guideline-driven recommendations. The article further highlights emerging advances in diagnostics and therapeutics, providing practical insights for clinicians regarding optimal screening practices and interventions to improve patient outcomes.

Introduction

Iron deficiency, with or without anemia, is the most common micronutrient deficiency in women globally. The clinical implications span fatigue, cognitive impairment, decreased immunity, and adverse pregnancy outcomes, underlining the importance of timely recognition and management. Despite advancements in understanding its pathophysiology and treatment, gaps in screening and diagnosis persist, especially in asymptomatic individuals or those with non-specific symptoms. This review aims to provide a comprehensive, evidence-based overview to guide healthcare professionals in identifying, evaluating, and treating iron deficiency and anemia in women.

Epidemiology / Disease Burden

Globally, anemia affects over 30% of women of reproductive age, with iron deficiency accounting for approximately half of these cases. Menstruating women, pregnant women, and those with chronic conditions are disproportionately affected. According to the World Health Organization (WHO), the prevalence of anemia in pregnant women exceeds 40% in many low- and middle-income countries, while rates in developed regions remain significant due to factors such as heavy menstrual bleeding, dietary insufficiency, and increased physiological demands. Iron deficiency without overt anemia is also common, often preceding frank anemia and contributing to subclinical morbidity. The economic and public health impacts are profound, encompassing reduced productivity, impaired maternal and child health, and increased healthcare utilization.

Pathophysiology

Iron homeostasis is tightly regulated, with dietary absorption in the duodenum balanced against losses and body demands. In women, physiological blood loss through menstruation and the increased iron requirements of pregnancy and lactation are principal contributors to negative iron balance. Iron deficiency develops when losses or requirements exceed intake or absorption, resulting in depleted iron stores (reflected by low ferritin), followed by impaired erythropoiesis and eventual anemia (low hemoglobin and hematocrit). Inflammatory states can further disrupt iron metabolism via hepcidin-mediated sequestration, complicating diagnosis and management in chronic disease settings.

Risk Factors

Key risk factors for iron deficiency and IDA in women include heavy menstrual bleeding (menorrhagia), multiparity, close birth spacing, vegetarian or vegan diets, gastrointestinal malabsorption (e.g., celiac disease, inflammatory bowel disease), bariatric surgery, chronic blood loss (e.g., from gastrointestinal lesions), and low socioeconomic status. Pregnancy markedly increases risk due to expanded maternal blood volume and fetal demands. Adolescents and athletes may also be predisposed due to growth and training-related losses, respectively. Recognizing these risk profiles is critical for targeted screening and prevention strategies.

Clinical Features

Iron deficiency may be asymptomatic or present with non-specific symptoms such as fatigue, weakness, decreased exercise tolerance, pallor, and cognitive difficulties. Pica (craving for non-nutritive substances), glossitis, angular cheilitis, and brittle nails (koilonychia) are classical but less common findings. In pregnancy, IDA is associated with increased risks of preterm birth, low birth weight, and peripartum complications. The subtlety of early symptoms often delays diagnosis, emphasizing the need for vigilant screening in at-risk women.

Diagnosis

Diagnostic evaluation involves a complete blood count (CBC) revealing microcytic, hypochromic anemia in advanced cases, and iron studies including serum ferritin, transferrin saturation, serum iron, and total iron-binding capacity (TIBC). Ferritin is the most sensitive marker of iron stores but is an acute-phase reactant and may be elevated in inflammatory states, necessitating interpretation in clinical context. Additional evaluation for underlying causes (e.g., gastrointestinal bleeding, malabsorption) is warranted in unexplained or refractory cases. Recent advances include reticulocyte hemoglobin content and soluble transferrin receptor assays, offering adjunctive diagnostic value.

Treatment & Management

Oral iron supplementation remains first-line therapy, with ferrous sulfate, gluconate, and fumarate among common formulations. Gastrointestinal side effects can limit adherence, prompting exploration of alternate-day dosing and novel preparations (e.g., polysaccharide-iron complex, heme iron polypeptide). Intravenous iron is reserved for severe deficiency, intolerance of oral therapy, or cases with ongoing significant blood loss or malabsorption. Addressing the underlying etiology (e.g., treating menorrhagia, managing GI lesions) is essential for sustained correction. In pregnancy, early supplementation is advocated to optimize maternal and fetal outcomes.

Recent Advances / Emerging Therapies

Emerging therapies include newer IV iron formulations with improved safety profiles and rapid repletion capability (e.g., ferric carboxymaltose, iron sucrose), as well as hepcidin antagonists under investigation for inflammatory anemia. Advances in point-of-care diagnostics and non-invasive screening tools are enhancing early detection, particularly in resource-limited settings. Ongoing research is elucidating the role of micronutrient co-supplementation and personalized dosing strategies to maximize efficacy and minimize side effects.

Guideline Recommendations

Major guidelines (e.g., WHO, CDC, ACOG) recommend targeted screening for iron deficiency and anemia in women at high risk, including all pregnant women at their first prenatal visit and non-pregnant women with risk factors such as heavy menstrual bleeding or a history of anemia. Universal screening in pregnancy is widely endorsed, while selective screening is advised for other groups. Laboratory thresholds for defining anemia and iron deficiency vary somewhat by guideline and population, underscoring the need for context-specific interpretation. Early recognition and intervention are prioritized to prevent complications and optimize health outcomes.

Conclusion

Iron deficiency and anemia remain significant, yet often underdiagnosed, sources of morbidity in women. A mechanistic understanding of risk factors, clinical manifestations, and diagnostic nuances is crucial for timely detection and effective management. Guideline-driven, individualized screening and therapeutic strategies can mitigate the burden of disease and improve quality of life for affected women. Ongoing research and emerging therapies hold promise for further advances in prevention, diagnosis, and treatment, underscoring the importance of continued vigilance and education among healthcare professionals.